CMS releases billing information for Regeneron monoclonal antibody

The Centers for Medicare & Medicaid Services has identified the Healthcare Common Procedural Coding System codes and Medicare Part B payment allowances effective Nov. 21 for administering casirivimab and imdevimab, a combination monoclonal antibody therapy made by Regeneron. The Department of Health and Human Services last month began allocating initial doses of the therapy to states and territories after the Food and Drug Administration authorized its emergency use to treat certain COVID-19 outpatients at risk for severe disease.